Medical Oncologist
Long-term TKI therapy
Years on a TKI: — Long-Term Effects and Whether You Can Stop
Years of daily TKI therapy cause some side effects your body adjusts to, and others that need watching over time. For patients who have held a deep response, stopping treatment is now a formally recognised goal in international guidelines — but only when it is planned, monitored, and timed correctly.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Some effects ease, some accumulate — Nausea and early cramps often settle. Fatigue and certain metabolic changes may not.
- Monitoring becomes part of long-term care — Annual cardiovascular and metabolic checks are recommended, not optional, on most TKIs.
- Stopping may become possible — Treatment-free remission is now in NCCN and ESMO guidelines for eligible patients.
- Stopping without a plan is risky — TFR requires an intensive monitoring schedule. Stopping pills quietly is not the same thing.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Years on a TKI cause some effects that ease as your body adapts, and others that need watching — particularly on the heart and blood vessels with some agents. NCCN and ESMO guidelines now recognise treatment-free remission as a realistic goal for patients who have held a deep molecular response for several years.
What side effects are still there after years on a TKI?
The most commonly reported long-term effect is fatigue. For many people it improves in the first year and then plateaus; for others it remains disruptive throughout treatment.
Muscle cramps and periorbital oedema — puffiness around the eyes — are common with imatinib and tend to remain stable rather than worsening over time. They do not typically signal anything dangerous, but they are worth mentioning to your oncologist if they affect daily life.
Nausea and gastrointestinal upset, which are often prominent early on, typically ease once your body adjusts. Diarrhoea can persist with some agents. Taking your tablet with a full meal and a large glass of water is one of the simplest adjustments that helps.
Which long-term effects need regular blood tests and monitoring?
ESMO and NCCN guidelines specifically flag cardiovascular risk with certain second-generation TKIs — nilotinib and ponatinib in particular. If you are on one of these, your team should be checking blood pressure, cholesterol, and blood glucose on a regular schedule and reviewing your overall heart risk each year.
Nilotinib can raise blood sugar and blood fats over time. These changes are detectable early with routine blood tests and are manageable when caught. They are not a reason to stop treatment, but they are a reason to keep every monitoring appointment.
Liver enzyme levels are checked for all patients on TKIs. Elevations are usually mild and resolve on their own; persistent or significant rises will prompt your oncologist to review the dose or the agent. Do not stop your TKI because of an abnormal result without first speaking to your team.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
Can you stop your TKI after years of a good response?
For some patients, yes. NCCN and ESMO guidelines now formally include treatment-free remission as a goal for patients who meet specific criteria. Those criteria generally include holding a deep molecular response for a sustained period alongside a minimum total time on treatment.
After stopping, the critical element is intensive molecular monitoring. Most patients who relapse molecularly do so within the first six months after stopping. Restarting TKI after a molecular relapse almost always re-achieves remission — which is why the monitoring plan, not the stopping itself, is what makes TFR safe.
This is a decision to make with your oncologist over time, not suddenly. If the idea interests you — whether because of fatigue, side effects, or simply wanting to know whether it is possible — that is a legitimate conversation to start at your next appointment.
What do the words on your test reports actually mean?
- Tyrosine kinase inhibitor (TKI)
- A daily tablet that blocks a specific protein driving certain cancers. In chronic myeloid leukaemia, that protein is produced by the BCR-ABL gene fusion. Imatinib, dasatinib, nilotinib, and bosutinib are all TKIs.
- BCR-ABL
- The gene fusion that drives chronic myeloid leukaemia. Your molecular blood test measures how much BCR-ABL is detectable. The result is expressed as a percentage on the international scale — the lower the number, the deeper the response.
- Deep molecular response (MR4 / MR4.5)
- A test result showing BCR-ABL has dropped to an extremely low level — so low it can barely be detected with standard testing, or in some cases not at all. Achieving and sustaining this level is the threshold considered when discussing treatment-free remission.
- Treatment-free remission (TFR)
- Stopping a TKI while remaining in remission, with close molecular monitoring. NCCN and ESMO now include it in guidelines as a defined goal for eligible patients. It is not the same as being told the disease is gone, but it is a recognised, monitored state.
- Molecular relapse
- When BCR-ABL becomes detectable again after stopping, signalling that TFR has not been sustained. This happens in a proportion of patients who attempt TFR. Restarting TKI almost always re-establishes remission.
Explore 39 more Monitoring, Resistance & Long-Term Response topics
Long-Term Response, Stopping & Survivorship
- Am I Still a Cancer Patient? Identity After Long-Term Response
- Bone Health, Heart Health and Late Effects to Monitor
- Can You Ever Stop Targeted Therapy If the Cancer Is Gone?
- Drug Holidays: Are Planned Breaks Safe?
- Follow-Up Schedule After Stopping Targeted Therapy
- How Long Do You Have to Stay on Targeted Therapy?
- Long-Term Effects of Taking a TKI for 5 or 10 Years
- Restarting Treatment After a Break
- Treatment-Free Remission in CML: Who Can Stop Their TKI?
- Your Survivorship Care Plan: What Should Be In It
Monitoring, Scans & Response Assessment
- Are Tumour Markers Reliable on Targeted Therapy?
- Complete Response, Partial Response, Stable Disease: What Each Means
- Do I Need Regular Brain MRIs on Targeted Therapy?
- How Doctors Measure Whether Targeted Therapy Is Working
- How Often Will I Need Scans on Targeted Therapy?
- How to Read a CT or PET Scan Report Without Panicking
- Is 'Stable Disease' Good News or Bad News?
- Scanxiety: How to Get Through the Wait for Scan Results
- Tumour Flare and Pseudoprogression: When Growth Isn't Really Growth
- Understanding PFS, OS and Median Survival Without Losing Hope
- What Happens at a Follow-Up Visit: A Walk-Through
- Which Blood Tests Are Repeated Every Month and Why
- ctDNA Monitoring: Can a Blood Test Predict Progression Early?
Resistance, Progression & Next Lines
- Being Told 'There Are No More Options': Is That Really True?
- Brain Metastases on Targeted Therapy: Does Your Drug Reach the Brain?
- Can You Continue the Same Drug After Progression?
- Combination Therapy to Overcome Resistance
- Do You Need Another Biopsy When the Cancer Progresses?
- Histologic Transformation: When Lung Cancer Changes Type
- How to Emotionally Process a Progression Scan
- Leptomeningeal Disease: Symptoms, Diagnosis and Treatment
- Life After ALK Inhibitor Resistance: Sequencing Your Options
- MET Amplification and Other Bypass Resistance Mechanisms
- Oligoprogression: When Only One or Two Spots Grow
- Primary vs Acquired Resistance: Two Very Different Problems
- Should You Change Hospitals After Progression?
- What Happens After Osimertinib Stops Working?
- What Is Sequencing and Why the Order of Drugs Matters
- Why Does Targeted Therapy Stop Working? The Biology of Resistance
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Will I need to take a TKI for the rest of my life?
Not necessarily. For patients with CML who have held a sustained deep molecular response, NCCN and ESMO guidelines now support discussing treatment-free remission as a goal. Whether it applies to you depends on how long you have been in deep remission and which TKI you are taking. This is a planned conversation with your oncologist, not a decision to make by stopping pills on your own.
What happens if I just stop taking my TKI without telling my doctor?
Without a monitoring plan, you lose the safety net that makes stopping safe. Most molecular relapses after stopping happen within the first six months, and without frequent blood tests you would not know until the disease had progressed beyond early detection. Treatment-free remission works because it pairs stopping with intensive monitoring — typically fortnightly blood tests — so your team can restart immediately if needed. Stopping quietly removes that protection entirely.
My fatigue has not improved after years on a TKI. Is that normal?
Persistent fatigue through long-term TKI therapy is common and real. It does not always mean something is wrong, but it is worth discussing with your oncologist because the cause is not always the TKI itself. Anaemia, thyroid changes, sleep disruption, and the weight of long-term treatment all contribute. Some of these are treatable. Some patients also find a different TKI is better tolerated, and that is a conversation worth having if fatigue is significantly affecting your daily life.
Does taking a TKI for years cause heart problems?
It depends on which TKI you are on. ESMO and NCCN guidelines specifically highlight cardiovascular risk with nilotinib and ponatinib, which are associated with arterial events over time. Imatinib has a more reassuring long-term cardiovascular profile. Whatever TKI you are taking, your team should be reviewing your blood pressure, blood fats, blood glucose, and overall heart risk on a regular basis — this is part of standard long-term care, not a sign that something is already wrong.
What does my BCR-ABL result actually mean?
BCR-ABL is the genetic marker your leukaemia is measured by. The result is expressed as a percentage on an international scale, where lower is better. MR4 and MR4.5 describe levels so low they can barely be detected with standard testing. Reaching and holding one of these levels for a sustained period is what makes treatment-free remission a realistic conversation. If you are not sure what your result means, ask your oncologist to explain it against your own trend over time rather than a single number.
My doctor has never mentioned stopping. Should I ask?
Yes, and you are not being difficult by raising it. Treatment-free remission is now in NCCN and ESMO guidelines, but it requires specific criteria to be met first — criteria your oncologist can check against your own results. Some patients meet those criteria without the topic having been raised. If you have been on a TKI for several years and your BCR-ABL results have been consistently at a deep level, it is reasonable to ask at your next appointment whether TFR has been considered for you.